このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

ダウン症および閉塞性睡眠時無呼吸症候群の小児および青少年に対する酸素療法 (DOSA)

2026年9月25日 更新者:Susan Redline、Brigham and Women's Hospital

ダウン症および閉塞性睡眠時無呼吸症候群の小児および青少年に対する酸素療法のランダム化対照試験

The purpose of this study is to assess whether oxygen supplementation during sleep improves working memory and other clinical and patient-reported outcomes among children who have Down Syndrome (DS) with moderate to severe Obstructive Sleep Apnea (OSA).

調査の概要

状態

募集

条件

介入・治療

詳細な説明

This will be a randomized, single-blind 6-month Phase-2 clinical trial that compares the impact of oxygen therapy during sleep on measures of cognition, behavior, quality of life, cardiac structure and function, and sleep in children with Down Syndrome(DS) with moderate to severe obstructive sleep apnea.

The proposed study will involve participation of children and their caregivers. Children will be recruited from each site's sleep clinics and laboratories, Down syndrome clinics and otolaryngology clinics. Community recruitment will be coordinated with local Down Syndrome Associations.

Children who agree to participate in the study will be screened for eligibility based on history, physical examination, and review of medical records including history of congenital heart disease and Pulmonary Hypertension (PHTN), and use of Continuous Positive Airway Pressure (CPAP). Children eligible for the study are those with persistent obstructive apnea after adenotonsillectomy or children with obstructive sleep apnea without adenotonsillar hypertrophy or in situations when parents refuse adenotonsillectomy.. The enrollment PSG eligibility will be determined by central scoring of either a research Polysomnography (PSG). In addition to an oxygen titration PSG, which determines responsiveness to oxygen, participants will be asked to wear a wrist actigraph and undergo neurocognitive testing, echocardiography, physical examination, anthropometry, and venipuncture. Caregivers will complete questionnaires to assess their child's emotional, physical, social, and school functioning, sleep quality; child's behavior and cognitive function, and will complete a sleep diary that is used concurrently with their child's use of a wrist actigraph. The latter includes caregiver completion of the "Behavior Rating Inventory of Executive Function" (BRIEF2), a co-primary outcome.

At 3 months, caregivers will complete the BRIEF2. At 6 months, all baseline studies and a PSG will be repeated.

At baseline, demographic data will be collected, including information on residential address (for use in geocoding).

研究の種類

介入

入学 (推定)

230

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • California
      • Los Angeles、California、アメリカ、90027
        • 募集
        • Children's Hospital of Los Angeles
        • コンタクト:
        • 主任研究者:
          • Sally Ward, MD
    • Michigan
      • Ann Arbor、Michigan、アメリカ、48109
        • 募集
        • University of Michigan, Ann Arbor Hospital
        • コンタクト:
        • 主任研究者:
          • Ronald Chervin, MD
    • Ohio
      • Cincinnati、Ohio、アメリカ、45229
        • 募集
        • Cincinnati Children's Hospital Medical Center
        • 主任研究者:
          • Raouf Amin, MD
        • コンタクト:
      • Cleveland、Ohio、アメリカ、44106
        • 募集
        • Rainbow Babies and Children's Hospital, Case Medical Center
        • コンタクト:
        • 主任研究者:
          • Sally Ibrahim, MD
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19104
        • 募集
        • Children's Hospital of Philadelphia
        • コンタクト:
        • 主任研究者:
          • Christopher Cielo, MD
    • Virginia
      • Norfolk、Virginia、アメリカ、23507
        • 募集
        • East Virginia Medical Center
        • コンタクト:
        • 主任研究者:
          • Cristina Baldassari, MD
    • Washington
      • Seattle、Washington、アメリカ、98105

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

5年~18年 (子、大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Ages 5.0 to 17.9 years at the time of screening

  2. Children with OSA and obstructive apnea hypopnea index (OAHI) ≥5/hour.

  3. Absence of clinically significant hypoxia defined as oxygen saturation <88% for 5 minutes or episodic desaturation to 60% as these levels would otherwise identify children eligible to routinely receive oxygen.

  4. Favorable response to oxygen therapy (allowing randomization) will be defined as follows:

    1. Oxygen saturation nadir >92% and
    2. Decrease in obstructive index < 5 / hour or by > 50% from screening PSG
    3. Reaching an optimum oxygen flow which is defined as the flow that achieves the lowest level of AHI with maximum CO2 level less than 65 mmHg observed for 5 consecutive minutes and or an increase in CO2 by less than 15 points above baseline. The above criteria are observed while the patient spends a minimal of 30 minutes in the supine position and at least one cycle of rapid eye movement (REM) sleep.
    4. Oxygen flow required does not exceed 3.0 LPM and does not exceed a FiO2 > 40 %.
  5. Willingness to comply with all study procedures and available for duration of study.

  6. At baseline the participant attempts to perform the neuropsychological tests

Exclusion Criteria:

  1. Current CPAP use with documented compliance(> 4 hrs/ night; > 70% of nights).
  2. Oxygen saturation < 90% at rest during wakefulness.
  3. Chronic daytime or nighttime use of supplemental oxygen.
  4. Smoker in the child's bedroom.
  5. Unrepaired congenital heart disease.
  6. Moderate to severe pulmonary hypertension requiring treatment with oxygen and or pulmonary vasodilator.
  7. Unable to participate in a PSG.
  8. Individuals who develop alveolar hypoventilation with oxygen as previously defined.
  9. Other severe chronic diseases determined by their provider as making them poor study candidates.
  10. Enrolled or planning to enroll in another study that may conflict with protocol requirements or confound results in this trial.
  11. Documented clinically significant untreated hypothyroidism
  12. Children with adenotonsillar hypertrophy who are candidates for adenotonsillectomy and parents agree to the surgery.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Oxygen plus supportive care (OXT)

Nocturnal oxygen therapy plus providing patient with healthy sleep habits materials, healthy diet materials and nasal dilators.

Active nocturnal oxygen concentrator

介入なし:Supportive care (SC)

Providing patient with healthy sleep habits materials, healthy diet materials and nasal dilators.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Behavior Rating Inventory of Executive Function 2 (BRIEF2) working memory score
時間枠:Baseline and 6 months

Change from baseline in the Behavior Rating Inventory of Executive Function 2 (BRIEF2) working memory score (BRIEF2wm). The score ranges from 35-90. A higher score is a worse outcome.

Baseline and 6 months
Differential Ability Scales - 2nd Edition (DAS-II) T-score.
時間枠:Baseline and 6 months

Change from baseline in the Differential Ability Scales - 2nd Edition (DAS-II) recognition of pictures (DAS2RoP) T-score. The score ranges from 10-90. A higher score is a better outcome.

Baseline and 6 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Total raw score
時間枠:Baseline and 6 Months

Change from baseline of Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Total raw score. The score ranges from 0-64. A higher score is a better outcome.

Baseline and 6 Months
Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Verbal raw score
時間枠:Baseline and 6 Months

Change from baseline of Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Verbal raw score. The score ranges from 0-30. A higher score is a better outcome.

Baseline and 6 Months
Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Non Verbal raw score
時間枠:Baseline and 6 Months

Change from baseline of Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Non Verbal raw score. The score ranges from 0-34. A higher score is a better outcome.

Baseline and 6 Months
Differential Ability Scales-2 (DAS-II) Recall of Digits Forward raw score
時間枠:Baseline and 6 Months

Change from baseline in Differential Ability Scales-2 (DAS-II) Recall of Digits Forward raw score. The score ranges from 0-38. A higher score is a better outcome.

Baseline and 6 Months
Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associates Learning (PAL) adjusted total errors based on stages completed
時間枠:Baseline and 6 Months

Change from baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associates Learning (PAL) adjusted total errors based on stages completed

Baseline and 6 Months
Cambridge Neuropsychological Test Automated Battery (CANTAB) Reaction Time (RTI)
時間枠:Baseline and 6 Months

Change from baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Reaction Time (RTI)

Baseline and 6 Months
Developmental Neuropsychological Assessment 2nd Edition (NEPSY-II) verbal fluency test raw score
時間枠:Baseline and 6 Months

Change from baseline in Developmental Neuropsychological Assessment 2nd Edition (NEPSY-II) verbal fluency test raw score. Range-N/A

Baseline and 6 Months
Observer Memory Questionnaire - Parent Form (OMQ-PF) total T-score
時間枠:Baseline and 6 Months

Change from baseline in Observer Memory Questionnaire - Parent Form (OMQ-PF) total T-score. The score ranges from 0-135. A higher score is a better outcome.

Baseline and 6 Months
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for subscales (Inhibit, Self-Monitor, Shift, Emotional Control, Initiate)
時間枠:Baseline and 6 Months

Change from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for subscales (Inhibit, Self-Monitor, Shift, Emotional Control, Initiate).

Baseline and 6 Months
Child Behavior Checklist (CBCL) T-scores for domains (Internalizing, Externalizing, Total Problems).
時間枠:Baseline and 6 Months

Change from baseline in Child Behavior Checklist (CBCL) T-scores for domains (Internalizing, Externalizing, Total Problems).

Baseline and 6 Months
Child Behavior Checklist (CBCL) T-scores for subscales (Attention Problems, Thought Problems, Rule-Breaking Behaviors, Aggressive Behaviors)
時間枠:Baseline and 6 Months

Change from baseline in Child Behavior Checklist (CBCL) T-scores for subscales (Attention Problems, Thought Problems, Rule-Breaking Behaviors, Aggressive Behaviors)

Baseline and 6 Months
KIDSCREEN-27 T-score
時間枠:Baseline and 6 Months

Change from baseline in KIDSCREEN-27 T-score, including domains of: physical well-being; psychological well-being; autonomy and parent relations; social support and peers; school environment. Range-N/A

Baseline and 6 Months
Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance T-score
時間枠:Baseline and 6 Months

Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance T-score. The score ranges from 28.7-85.6. A higher score is a worse outcome.

Baseline and 6 Months
Patient-Reported Outcomes Measurement Information System (PROMIS) sleep-related impairment T-score
時間枠:Baseline and 6 Months

Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) sleep-related impairment T-score. The score ranges from 37.9-86.6. A higher score is a worse outcome.

Baseline and 6 Months
Presence of right ventricular hypertension
時間枠:Baseline and 6 Months

Presence of right ventricular hypertension as measured by tricuspid regurgitation continuous wave peak velocity (defined as a ratio of pulmonary artery pressure / systolic arterial pressure (PAP/SAP) >1/3); interventricular septal flattening as measured by eccentricity index (defined as systolic ratio of >1.25)

Baseline and 6 Months
Wechsler Intelligence Scale (WISC) for Children 5th edition (WISC-5) Cancellation raw score
時間枠:Baseline and 6 Months

Change from baseline of Wechsler Intelligence Scale (WISC) for Children 5th edition (WISC-5) Cancellation raw score. The score ranges from 0-128. A higher score is a better outcome.

Baseline and 6 Months
Wechsler Preschool and Primary Scale of Intelligence 4th edition (WPPSI-4) Cancellation task raw score
時間枠:Baseline and 6 Months

Change from baseline in Wechsler Preschool and Primary Scale of Intelligence 4th edition (WPPSI-4) Cancellation task raw score (if unable to complete Wechsler Intelligence Scale 5th edition Cancellation test). The score ranges from 0-96. A higher score is a better outcome.

Baseline and 6 Months
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Behavior Regulation Index (BRI) domain.
時間枠:Baseline and 6 Months

Change from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Behavior Regulation Index (BRI) domain. The score ranges from 35-90. A higher score is a worse outcome.

Baseline and 6 Months
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Emotional Recognition Index (ERI) domain.
時間枠:Baseline and 6 Months

Change from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Emotional Recognition Index (ERI) domain. The score ranges from 35-90. A higher score is a worse outcome.

Baseline and 6 Months
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Cognitive Regulation Index (CRI) domain.
時間枠:Baseline and 6 Months

Change from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Cognitive Regulation Index (CRI) domain. The score ranges from 35-90. A higher score is a worse outcome.

Baseline and 6 Months
7-day actigraphy measurement of sleep efficiency
時間枠:Baseline and 6 Months

Change from baseline in 7-day actigraphy measurement of sleep efficiency

Baseline and 6 Months
7-day actigraphy measurement of time wake after sleep onset
時間枠:Baseline and 6 Months

Change from baseline in 7-day actigraphy measurement of time wake after sleep onset

Baseline and 6 Months
7-day actigraphy measurement of sleep fragmentation
時間枠:Baseline and 6 Months

Change from baseline in 7-day actigraphy measurement of sleep fragmentation

Baseline and 6 Months
7-day actigraphy measurement of total sleep duration
時間枠:Baseline and 6 Months

Change from baseline in 7-day actigraphy measurement of total sleep duration

Baseline and 6 Months
Polysomnography (PSG) AHI parameter
時間枠:Baseline and 6 Months

Change from baseline in Polysomnography (PSG) AHI parameter. The score ranges from 0- >40. A higher score is a worse outcome.

Baseline and 6 Months
Polysomnography (PSG) percentage time of O2 <90 % parameter
時間枠:Baseline and 6 Months

Change from baseline in Polysomnography (PSG) percentage time of O2 <90 % parameter

Baseline and 6 Months
Polysomnography (PSG) sleep apnea associated hypoxic burden parameter
時間枠:Baseline and 6 Months

Change from baseline in Polysomnography (PSG) sleep apnea associated hypoxic burden, parameter

Baseline and 6 Months
Polysomnography (PSG) end-tidal CO2 level, parameter
時間枠:Baseline and 6 Months

Change from baseline in Polysomnography (PSG) end-tidal CO2 parameter.

Baseline and 6 Months
Polysomnography (PSG) -based measure of sleep stages
時間枠:Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of sleep stages. Range- N/A

Baseline and 6 Months
Polysomnography (PSG) -based measure of EEG power bands
時間枠:Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of EEG power bands

Baseline and 6 Months
Polysomnography (PSG) -based measure of spindle morphology
時間枠:Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of spindle morphology

Baseline and 6 Months
Polysomnography (PSG) -based measure of spindle numbers
時間枠:Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of spindle numbers

Baseline and 6 Months
Polysomnography (PSG) -based measure of spindle density
時間枠:Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of spindle density

Baseline and 6 Months
Polysomnography (PSG) -based measure of slow wave oscillations
時間枠:Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of slow wave oscillations

Baseline and 6 Months
Left ventricular diastolic function as measured by Mitral E and A wave (E:A ratio)
時間枠:Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Mitral E and A wave (E:A ratio)

Baseline and 6 Months
Left ventricular diastolic function as measured by E wave deceleration time
時間枠:Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by E wave deceleration time

Baseline and 6 Months
Left ventricular diastolic function as measured by Mitral septal and lateral e' and a' (E/e')
時間枠:Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Mitral septal and lateral e' and a' (E/e')

Baseline and 6 Months
Left ventricular diastolic function as measured by Mitral lateral tissue Doppler isovolumic relaxation time
時間枠:Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Mitral lateral tissue Doppler isovolumic relaxation time

Baseline and 6 Months
Left ventricular diastolic function as measured by Pulmonary vein A wave reversal duration
時間枠:Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Pulmonary vein A wave reversal duration

Baseline and 6 Months
Left ventricular diastolic function as measured by Left atrial volume
時間枠:Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Left atrial volume

Baseline and 6 Months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Susan Redline、Brigham and Women's Hospital
  • 主任研究者:Raouf Amin、Children's Hospital Medical Center, Cincinnati

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年10月24日

一次修了 (推定)

2027年11月30日

研究の完了 (推定)

2027年12月30日

試験登録日

最初に提出

2023年8月17日

QC基準を満たした最初の提出物

2023年9月12日

最初の投稿 (実際)

2023年9月21日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月30日

QC基準を満たした最後の更新が送信されました

2026年9月25日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2023P000062

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。